+关注
毋所事事
暂无个人介绍
IP属地：未知
23
关注
1
粉丝
4
主题
0
勋章
主贴
热门
毋所事事
2020-02-14
利好？
快讯|默沙东：Keytruda联合化疗达到无进展生存期的主要终点
毋所事事
2019-03-22
$高通(QCOM)$看好后市
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3450003023906401","uuid":"3450003023906401","gmtCreate":1486909003452,"gmtModify":1611571111002,"name":"毋所事事","pinyin":"wssswusuoshishi","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/dd9aaf594337ff049eb0049203d0c26e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":23,"tweetSize":2,"questionSize":0,"limitLevel":900,"accountStatus":3,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":4,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":917182709,"gmtCreate":1581644856601,"gmtModify":1704344867060,"author":{"id":"3450003023906401","authorId":"3450003023906401","name":"毋所事事","avatar":"https://static.tigerbbs.com/dd9aaf594337ff049eb0049203d0c26e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3450003023906401","authorIdStr":"3450003023906401"},"themes":[],"htmlText":"利好？","listText":"利好？","text":"利好？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/917182709","repostId":"2011750324","repostType":2,"repost":{"id":"2011750324","pubTimestamp":1581561016,"share":"https://www.laohu8.com/m/news/2011750324?lang=&edition=full","pubTime":"2020-02-13 10:30","market":"us","language":"zh","title":"快讯|默沙东：Keytruda联合化疗达到无进展生存期的主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2011750324","media":"财经网","summary":"财经网产经讯 据即刻药闻信息，2月12日，默沙东宣布，Keytruda（pembrolizumab）联合化疗（白蛋白结合型紫杉醇、紫杉醇或吉西他滨/卡铂），在一线治疗肿瘤表达PD-L1（联合阳性评分[","content":"<div>\n<p>财经网产经讯 据即刻药闻信息，2月12日，默沙东宣布，Keytruda（pembrolizumab）联合化疗（白蛋白结合型紫杉醇、紫杉醇或吉西他滨/卡铂），在一线治疗肿瘤表达PD-L1（联合阳性评分[CPS]≥10）的转移性三阴性乳腺癌（mTNBC）的关键3期KEYNOTE-355临床试验中达到无进展生存期(PFS)的主要终点。基于独立数据监查委员会(DMC)进行的中期分析，Keytruda联合...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020021310314279a9475d&s=b\">Web Link</a>\n\n</div>\n","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>快讯|默沙东：Keytruda联合化疗达到无进展生存期的主要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n快讯|默沙东：Keytruda联合化疗达到无进展生存期的主要终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-02-13 10:30 北京时间 <a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020021310314279a9475d&s=b><strong>财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>财经网产经讯 据即刻药闻信息，2月12日，默沙东宣布，Keytruda（pembrolizumab）联合化疗（白蛋白结合型紫杉醇、紫杉醇或吉西他滨/卡铂），在一线治疗肿瘤表达PD-L1（联合阳性评分[CPS]≥10）的转移性三阴性乳腺癌（mTNBC）的关键3期KEYNOTE-355临床试验中达到无进展生存期(PFS)的主要终点。基于独立数据监查委员会(DMC)进行的中期分析，Keytruda联合...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020021310314279a9475d&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","relate_stocks":{"MRK":"默沙东"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020021310314279a9475d&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2011750324","content_text":"财经网产经讯 据即刻药闻信息，2月12日，默沙东宣布，Keytruda（pembrolizumab）联合化疗（白蛋白结合型紫杉醇、紫杉醇或吉西他滨/卡铂），在一线治疗肿瘤表达PD-L1（联合阳性评分[CPS]≥10）的转移性三阴性乳腺癌（mTNBC）的关键3期KEYNOTE-355临床试验中达到无进展生存期(PFS)的主要终点。基于独立数据监查委员会(DMC)进行的中期分析，Keytruda联合化疗的一线治疗，与单独化疗相比，PFS出现了具有统计学意义和临床意义的改善。根据DMC的建议，试验将继续进行，以评价另一个双重主要终点总生存期(OS)。默沙东表示，将与监管机构沟通这次试验的数据，并且在即将到来的医学会议上公布研究结果。目前，默沙东正在开展关于Keytruda治疗乳腺癌的多项内部和外部合作的临床开发，包括三项正在进行的TNBC注册研究（KEYNOTE-355，KEYNOTE-242和KEYNOTE-522）。Merck研究实验室总裁 Roger M. Perlmutter 博士表示：“这是个非常令人鼓舞的结果，Keytruda联合化疗作为治疗转移性TNBC的一线疗法（本次KEYNOTE-355试验），以及作为新辅助疗法（KEYNOTE-522 试验），均表现出积极的结果。”","news_type":1},"isVote":1,"tweetType":1,"viewCount":981,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":440216,"gmtCreate":1553251040744,"gmtModify":1704794482848,"author":{"id":"3450003023906401","authorId":"3450003023906401","name":"毋所事事","avatar":"https://static.tigerbbs.com/dd9aaf594337ff049eb0049203d0c26e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3450003023906401","authorIdStr":"3450003023906401"},"themes":[],"htmlText":"$高通(QCOM)$看好后市","listText":"$高通(QCOM)$看好后市","text":"$高通(QCOM)$看好后市","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/440216","isVote":1,"tweetType":1,"viewCount":900,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":917182709,"gmtCreate":1581644856601,"gmtModify":1704344867060,"author":{"id":"3450003023906401","authorId":"3450003023906401","name":"毋所事事","avatar":"https://static.tigerbbs.com/dd9aaf594337ff049eb0049203d0c26e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3450003023906401","authorIdStr":"3450003023906401"},"themes":[],"htmlText":"利好？","listText":"利好？","text":"利好？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/917182709","repostId":"2011750324","repostType":2,"repost":{"id":"2011750324","pubTimestamp":1581561016,"share":"https://www.laohu8.com/m/news/2011750324?lang=&edition=full","pubTime":"2020-02-13 10:30","market":"us","language":"zh","title":"快讯|默沙东：Keytruda联合化疗达到无进展生存期的主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2011750324","media":"财经网","summary":"财经网产经讯 据即刻药闻信息，2月12日，默沙东宣布，Keytruda（pembrolizumab）联合化疗（白蛋白结合型紫杉醇、紫杉醇或吉西他滨/卡铂），在一线治疗肿瘤表达PD-L1（联合阳性评分[","content":"<div>\n<p>财经网产经讯 据即刻药闻信息，2月12日，默沙东宣布，Keytruda（pembrolizumab）联合化疗（白蛋白结合型紫杉醇、紫杉醇或吉西他滨/卡铂），在一线治疗肿瘤表达PD-L1（联合阳性评分[CPS]≥10）的转移性三阴性乳腺癌（mTNBC）的关键3期KEYNOTE-355临床试验中达到无进展生存期(PFS)的主要终点。基于独立数据监查委员会(DMC)进行的中期分析，Keytruda联合...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020021310314279a9475d&s=b\">Web Link</a>\n\n</div>\n","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>快讯|默沙东：Keytruda联合化疗达到无进展生存期的主要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n快讯|默沙东：Keytruda联合化疗达到无进展生存期的主要终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-02-13 10:30 北京时间 <a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020021310314279a9475d&s=b><strong>财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>财经网产经讯 据即刻药闻信息，2月12日，默沙东宣布，Keytruda（pembrolizumab）联合化疗（白蛋白结合型紫杉醇、紫杉醇或吉西他滨/卡铂），在一线治疗肿瘤表达PD-L1（联合阳性评分[CPS]≥10）的转移性三阴性乳腺癌（mTNBC）的关键3期KEYNOTE-355临床试验中达到无进展生存期(PFS)的主要终点。基于独立数据监查委员会(DMC)进行的中期分析，Keytruda联合...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020021310314279a9475d&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","relate_stocks":{"MRK":"默沙东"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020021310314279a9475d&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2011750324","content_text":"财经网产经讯 据即刻药闻信息，2月12日，默沙东宣布，Keytruda（pembrolizumab）联合化疗（白蛋白结合型紫杉醇、紫杉醇或吉西他滨/卡铂），在一线治疗肿瘤表达PD-L1（联合阳性评分[CPS]≥10）的转移性三阴性乳腺癌（mTNBC）的关键3期KEYNOTE-355临床试验中达到无进展生存期(PFS)的主要终点。基于独立数据监查委员会(DMC)进行的中期分析，Keytruda联合化疗的一线治疗，与单独化疗相比，PFS出现了具有统计学意义和临床意义的改善。根据DMC的建议，试验将继续进行，以评价另一个双重主要终点总生存期(OS)。默沙东表示，将与监管机构沟通这次试验的数据，并且在即将到来的医学会议上公布研究结果。目前，默沙东正在开展关于Keytruda治疗乳腺癌的多项内部和外部合作的临床开发，包括三项正在进行的TNBC注册研究（KEYNOTE-355，KEYNOTE-242和KEYNOTE-522）。Merck研究实验室总裁 Roger M. Perlmutter 博士表示：“这是个非常令人鼓舞的结果，Keytruda联合化疗作为治疗转移性TNBC的一线疗法（本次KEYNOTE-355试验），以及作为新辅助疗法（KEYNOTE-522 试验），均表现出积极的结果。”","news_type":1},"isVote":1,"tweetType":1,"viewCount":981,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":440216,"gmtCreate":1553251040744,"gmtModify":1704794482848,"author":{"id":"3450003023906401","authorId":"3450003023906401","name":"毋所事事","avatar":"https://static.tigerbbs.com/dd9aaf594337ff049eb0049203d0c26e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3450003023906401","authorIdStr":"3450003023906401"},"themes":[],"htmlText":"$高通(QCOM)$看好后市","listText":"$高通(QCOM)$看好后市","text":"$高通(QCOM)$看好后市","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/440216","isVote":1,"tweetType":1,"viewCount":900,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
